13 recruiting, 8 active not recruiting, 4 terminated, 3 completed. 22 Phase 2, 8 Phase 1, 4 Phase 3, 1 Not applicable.
Follow Metastatic Prostate Adenocarcinoma: new trials by email Literature Review of Metastatic Prostate Adenocarcinoma trials Research Report on Metastatic Prostate Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2026-10-01 | 2026-08-28 | |
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-06-01 | 2026-05-05 |
| Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1524 | 2026-03-31 | 2026-10-02 |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial Androgen Therapy, Apalutamide, Docetaxel - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1260 | 2025-12-01 | 2026-10-02 |
| Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Anti-STEAP1 CAR T-cells, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 48 | 2024-11-26 | 2026-08-11 |
| Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 15 | 2024-09-18 | 2026-08-06 |
| Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Washington | 69 | 2024-05-21 | 2026-07-21 |
| CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2024-03-05 | 2026-07-22 |
| Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients High Intensity Interval Training - Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer | Not applicable | Withdrawn | The University of Texas Health Science Center at San Antonio | 2023-12-01 | 2024-02-26 | |
| Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer Abiraterone, Biospecimen Collection, Bone Scan - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 | Terminated | Emory University | 4 | 2023-08-03 | 2025-09-15 |
| Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer VLP-encapsulated TLR9 Agonist CMP-001,, Nivolumab - Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 | Phase 2 | Suspended | Emory University | 10 | 2023-06-07 | 2026-10-13 |
| Measuring Oncological Value of Exercise and Statin Guided physical exercise, Atorvastatin, Independent exercise - Prostate Cancer, Breast Cancer | Phase 3 | Recruiting | Tampere University Hospital | 240 | 2023-03-31 | 2025-06-27 |
| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Abemaciclib, Lutetium Lu 177-PSMA-617 - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Vadim S Koshkin | 30 | 2022-07-08 | 2026-07-24 |
| Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer Cyclophosphamide, Dexamethasone - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 | Active not recruiting | Rashmi Verma, MD | 7 | 2022-06-29 | 2025-01-08 |
| Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) radium-223, Bipolar Androgen Therapy (BAT) - Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 47 | 2022-04-28 | 2026-02-06 |
| Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Atezolizumab, Cabozantinib S-malate - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Active not recruiting | University of Utah | 31 | 2022-03-29 | 2026-10-14 |
| Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones Questionnaire Administration, Tin Sn 117m Pentetate - Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2021-12-18 | 2025-10-03 |
| A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy Enzalutamide, Rucaparib camsylate, Placebo - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 61 | 2021-10-14 | 2026-02-05 |
| Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Erdafitinib - Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents | Phase 2 | Terminated | M.D. Anderson Cancer Center | 11 | 2021-07-15 | 2026-02-06 |
Showing 20 of 33. Sign in to see all of them.
Prostatic Neoplasms (29) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Disease Progression (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Motor Activity (1) · Ovarian Neoplasms (1)
Genital Diseases (29) · Genital Diseases, Male (29) · Genital Neoplasms, Male (29) · Male Urogenital Diseases (29) · Neoplasms (29) · Neoplasms by Site (29) · Prostatic Diseases (29) · Urogenital Diseases (29) · Urogenital Neoplasms (29) · Breast Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Behavior (1)
Magnetic Resonance Spectroscopy (10) · Specimen Handling (10) · Biopsy (6) · enzalutamide (6) · X-Rays (5) · Abiraterone Acetate (4) · Leuprolide (4) · Pluvicto (4) · Photons (3) · Prednisone (3) · deltacortene (3) · luprolide acetate gel depot (3) · prednylidene (3) · Cyclophosphamide (2) · Docetaxel (2)
Alliance for Clinical Trials in Oncology (3) · Mayo Clinic (3) · National Cancer Institute (NCI) (3) · Emory University (2) · Fred Hutchinson Cancer Center (2) · M.D. Anderson Cancer Center (2) · Beth Israel Deaconess Medical Center (1) · City of Hope Medical Center (1) · Hellenic Cooperative Oncology Group (1) · Jonsson Comprehensive Cancer Center (1) · Kuopio University Hospital (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Rahul Aggarwal (1) · Rashmi Verma, MD (1)
United States (28) · Finland (2) · Brazil (1) · France (1) · Greece (1)
Michael Schweizer (2) · Zin W Myint (2) · Alexandra Sokolova, M.D. (1) · Amar Kishan (1) · Arpit Rao, MD (1) · Bassel Nazha, MD, MPH (1) · Brian J. Davis, M.D. (1) · Christopher J Logothetis (1) · Daniel S. Childs, MD (1) · Darpan I Patel, PhD (1) · David Einstein, MD (1) · Joseph R Osborne, M.D. (1) · Maha H Hussain, M.D. (1) · Matthew K. Tollefson, MD (1)
PMID 35428207, PMID 36210299, PMID 38494380
P50CA097186 (2), UM1CA186712 (2), 2019 (1), P30CA033572 (1), P30CA042014 (1), P30CA060553 (1), P30CA093373 (1), P30CA138292 (1), R01CA207645 (1), R37CA286450 (1), U10CA180821 (1), UM1CA186689 (1)